2024
Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink
Denoble A, Vazquez-Benitez G, Sheth S, Ackerman-Banks C, DeSilva M, Zhu J, Daley M, Getahun D, Klein N, Vesco K, Irving S, Nelson J, Williams J, Hambidge S, Donahue J, Weintraub E, Kharbanda E, Lipkind H. Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstetrics And Gynecology 2024, 144: 215-222. PMID: 38843526, PMCID: PMC11250101, DOI: 10.1097/aog.0000000000005632.Peer-Reviewed Original ResearchVaccine Safety DatalinkAntepartum stillbirthVaccine Safety Datalink sitesLive birthsCOVID-19 vaccineVaccine dosePregnancy start dateRisk of severe morbidityRisk of stillbirthConditional logistic regressionCase-control studyVaccine manufacturersSingleton pregnanciesGestational ageFetal deathPostpartum visitMaternal ageIndex dateSevere morbidityDiagnostic codesPregnancyStillbirthPregnant peopleCOVID-19Logistic regression
2021
Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Ellingson MK, Oliveira CR, Sheth SS, Sullivan EL, Torres A, Shapiro ED, Niccolai LM. Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis. BMC Public Health 2021, 21: 1283. PMID: 34193100, PMCID: PMC8247221, DOI: 10.1186/s12889-021-11340-4.Peer-Reviewed Original ResearchConceptsMid-adult womenVaccine receiptCross-sectional analysisHPV vaccineOngoing case-control studyReceipt of influenzaHealth care visitsCase-control studyWomen ages 24Quarter of adultsLogistic regression analysisCare visitsIndividual vaccinesHealthcare utilizationMultiple vaccinesVaccineAge 24White womenWomenDemographic characteristicsRegression analysisLower ratesInfluenzaReceiptPast yearEffectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study
Oliveira CR, Ortiz AM, Sheth SS, Shapiro ED, Niccolai LM. Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study. BMJ Open 2021, 11: e043093. PMID: 33875441, PMCID: PMC8057558, DOI: 10.1136/bmjopen-2020-043093.Peer-Reviewed Case Reports and Technical NotesConceptsHigh-grade cervical lesionsPre-licensure clinical trialsHPV vaccineCase-control studyNumber of dosesClinical trialsFirst human papillomavirus (HPV) vaccineMultivariate conditional logistic regressionNormal Pap test resultsReal-world clinical settingHuman papillomavirus vaccinePap test resultsHPV types 16Time of immunisationReal-world effectivenessConditional logistic regressionInstitutional review boardDate of testingPapillomavirus vaccineCervical lesionsPotential confoundersVaccine programMedical recordsPersistent infectionType 16